Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05048680
Recruiting Not applicable

Effect of Hypoxic Conditioning on Cerebrovascular Health in the Elderly

NCT05048680 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2021-10-13
Last updated
2026-05-08

Condition(s) studied

HypoxiaCerebral HypoxiaBrain DiseasesExerciseAgingCognitive DeclineHealthy Aging

Investigational drug(s) / intervention(s)

Hypoxia and/or Exercise

Hypoxia and/or Exercise: Hypoxia at rest versus normoxia at rest; Hypoxia during exercise versus Normoxia during exercise.

Study summary

In line with the ever-growing aging of Western populations, the development of preventive strategies to slow down the effects of aging on cardiovascular health represents a major challenge in order to preserve functional capacities and a sufficient quality of life in the elderly. The alteration of vascular function (at the cerebral and systemic level) with aging is an important feature in the clinical picture including a decrease in physical and cognitive capacities. Although physical activity is recognized as an essential means of combating the effects of aging, optimizing its effects by defining the most effective strategies of practice remains a key objective. Offering alternative interventions to exercise training is also necessary for people who are unwilling or unable to engage in a physical activity program. In this context, hypoxic conditioning, alone or in conjunction with rehabilitative exercise training, is a new therapeutic modality with strong preclinical validity, in particular from a cardiovascular standpoint, and used in other pathologies to improve cardiovascular function and exercise performance and quality of life. Our aim is, therefore, to investigate the effect of hypoxic conditioning (alone or in conjunction with exercise training) on cerebrovascular health in the elderly.

Eligibility

Sex
ALL
Min age
60 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * 60 to 80 years of age; * Being physically inactive (less than 150 min/week of moderate to intense physical activity); * No chronic cardiovascular, respiratory, metabolic or neuromuscular disease counterindicating an exercise training or hypoxic conditioning program; * Health coverage; * Being able to provide written fully informed consent. Exclusion Criteria: * Body-mass index \>30 kg/m2; * Smoking (\> cigarettes/day); * Alcohol use (\> 10g/day); * Mental disorder or history of mental disorder; * Beta-blockade treatment; * Inability or refusal to provide informed consent; * No health coverage * People exceeding the annual ceiling of allowances received as a result of their participation in other clinical trials; * People deprived of freedom by judicial or administrative decision; * People subject to legal protection, who cannot be included in clinical trials.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHU Grenoble Alpes La Tronche Auvergne-Rhône-Alpes Recruiting

More University Hospital, Grenoble trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05048680 on ClinicalTrials.gov ↗ ← All trials in France